In this issue:
Continuous guselkumab over 4 years in moderate-to-severe psoriasis
Nail and skin clearance with ixekizumab
Treatment discontinuation in psoriasis with ustekinumab and other biologics
Infections in children and adolescents treated with dupilumab
Dupilumab in Chinese patients with moderate-to-severe atopic dermatitis
Sexual dysfunction in moderate-to-severe atopic dermatitis
Adalimumab in patients with hidradenitis suppurativa
Omalizumab for anti-histamine refractory chronic spontaneous urticaria
Please login below to download this issue (PDF)